MEN1112/OBT357, an Anti Bst1/CD157 Humanized Antibody Inducing Acute Myelogenous Leukemia (AML) Blast Depletion in an Autologous Ex Vivo Assay: A Potential New Targeted Therapy for AML
Adriano Venditti(University of Rome Tor Vergata), Giuseppe Sconocchia(National Academies of Sciences, Engineering, and Medicine), Daniela Bellarosa(Menarini Group (Italy)), Roberto Arriga(University of Rome Tor Vergata), Luca Maurillo(University of Rome Tor Vergata), Stefano Manzini(University of Milan), Maria Ilaria Del Principe(University of Rome Tor Vergata), Patrizia Palomba(University of Rome Tor Vergata), Andrea Coppola(University of Rome Tor Vergata), Sergio Amadori(Polyclinic Medical Center), Monica Binaschi(Menarini Group (Italy)), Alessandro Bressan(Menarini Group (Italy)), Angela Capriati(Menarini Group (Italy)), Keith E. Wilson(Jet Propulsion Laboratory), Cecilia Simonelli(Menarini Group (Italy)), Francesco Buccisano(University of Rome Tor Vergata)
Cited by 4
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k